[Federal Register Volume 81, Number 155 (Thursday, August 11, 2016)]
[Notices]
[Pages 53162-53163]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-19035]


-----------------------------------------------------------------------

 DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical CBRN Defense Consortium (Formerly 
National Chemical Biological Defense Consortium)

    Notice is hereby given that, on June 23, 2016, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), National Chemical Biological 
Defense Consortium (``NCBDC'') has filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing changes in its membership. The notifications were 
filed for the purpose of extending the Act's provisions limiting the 
recovery of antitrust plaintiffs to actual damages under specified 
circumstances. National Chemical & Biological Defense Consortium 
(``NCBDC'') has changed its name to Medical CBRN Defense Consortium 
(``MCDC''). Specifically, AdjuvanceTechnologies, Inc., New York, NY; 
AEQUOR, Inc., Oceanside, CA; AktiVax, Inc., Boulder, CO; Alchem 
Laboratories Corp., Alachua, FL; Artificial Cell Technologies, Inc., 
New Haven, CT; Bach Pharma, Inc., North Andover, MA; Battelle Memorial 
Institute, Columbus, OH; Bryllan LLC, Brighton, MI; Creare LLC, 
Hanover, NH; CUBRC, Inc., Buffalo, NY; Data Sciences International, 
Inc., St. Paul, MN; First Line Technology, LLC, Chantilly, VA; Ginkgo 
Bioworks, Boston, MA; Harris Corporation, Herndon, VA; IIT Research 
Institute, Chicago, IL; Integrated Biotherapeutics, Inc., Gaithersburg, 
MD; InvivoSciences, Inc., Madison, WI; Joint Research and Development, 
Inc., Stafford, VA; Mapp BioPharmaceuticals, San Diego, CA; MaxCyte, 
Incorporated, Gaithersburg, MD; MRIGlobal, Kansas City, MO; 
Nanotherapeutics, Inc., Alachua, FL; Philips Healthcare, Andover, MA; 
Profectus BioSciences, Inc., Baltimore, MD; ProModel Corporation, 
Allentown, PA; QuickSilver Analytics, Inc., Belcamp, MD; SciTech 
Services, Inc., Havre de Grace, MD; SENTEL Corporation, Alexandria, VA; 
Shield Analysis Technology, LLC, Manassas, VA; Southwest Research 
Institute, San Antonio, TX; SRI International, Menlo Park, CA; Tech62, 
Fairfax, VA; Triton Systems, Inc., Chelmsford, MA; University of 
Pittsburgh, Pittsburgh, PA; University of Tennessee, Knoxville, 
Knoxville, TN; and Verndari Inc., Napa,

[[Page 53163]]

CA, have been added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MCDC intends to file additional 
written notifications disclosing all changes in membership.
    On November 13, 2015, NCBDC filed its original notification 
pursuant to Section 6(a) of the Act. The Department of Justice 
published a notice in the Federal Register pursuant to Section 6(b) of 
the Act on January 6, 2016 (81 FR 513).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2016-19035 Filed 8-10-16; 8:45 am]
 BILLING CODE 4410-11-P